. 2021 Feb 26;147(5):1341–1354. doi: 10.1007/s00432-021-03541-6

Table 3.

The criteria combining the validated marker CpG sites, cg17206555 (position 1), cg02046247 (position 1), and cg19918599 (position 2), for prediction of early recurrence (ER) of pancreatic ductal adenocarcinoma

Number of CpG sites satisfying the criteria shown in Table 2	Initial cohort		Validation cohort
	Sensitivity^a (%)	Specificity^b (%)	Sensitivity^a (%)	Specificity^b (%)
One or more	100	46.7	88.9	25.3
Two or three	81.8	71.7	88.9	70.4
Three	54.6	86.7	55.6	88.9

^aSensitivity is defined as the ratio of the number of tissue samples diagnosed as belonging to the ER group based on the criteria relative to the exact number of the patients belonging to the ER group

^bSpecificity is defined as the ratio of the number of tissue samples not diagnosed as belonging to the ER group using the criteria employed, relative to the exact number of patients belonging to the non-ER group